NEW YORK (GenomeWeb) – Chinese firms Shuwen Biotech and Jiangsu Hengrui Medicine today announced a collaboration to develop companion diagnostics.

Under the term of the agreement, Shuwen will develop assays and kits for an unidentified anticancer drug candidate that Hengrui is currently developing. Shuwen will also screen patients with the tests at its diagnostic reference laboratories for upcoming clinical trials, as well as manufacture and market the diagnostic if it receives regulatory approval.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.